| Outcome | Trial, n | SGLT2i, n | Placebo, n | Mean difference [95%CI] | Heterogeneity (%) | Test for the overall effect (p value) |
---|---|---|---|---|---|---|---|
Only Japanese patients | HbA1c (%) | 13 | 1998 | 866 | − 0.83 [− 1.01, − 0.65] | 90 | < 0.00001 |
TG (mg/dL) | 13 | 2127 | 848 | −14.39 [−20.80, −7.98] | 0 | < 0.0001 | |
HDL-C (mg/dL) | 12 | 1945 | 794 | 3.58 [2.90, 4.25] | 0 | < 0.00001 | |
LDL-C (mg/dL) | 12 | 1945 | 794 | 2.59 [0.72, 4.46] | 0 | 0.007 | |
LDL-C/HDL-C ratio | 2 | 402 | 125 | −0.04 [−0.12, 0.04] | 0 | 0.33 | |
Only patients treated with SGLT2i as monotherapy | HbA1c (%) | 8 | 1596 | 647 | −0.84 [− 0.97, − 0.70] | 77 | < 0.00001 |
TG (mg/dL) | 7 | 1464 | 497 | −17.96 [−27.03, −8.88] | 0 | 0.0001 | |
HDL-C (mg/dL) | 6 | 1282 | 443 | 3.89 [3.01, 4.76] | 0 | < 0.00001 | |
LDL-C (mg/dL) | 6 | 1282 | 443 | 4.29 [1.81, 6.76] | 0 | 0.0007 | |
LDL-C/HDL-C ratio | 1 | 307 | 75 | −0.04 [−0.13, 0.05] | NA | 0.37 |